A preliminary nomogram model for predicting relapse of patients with primary membranous nephropathy

Abstract Objective To explore the predictive factors and establish a nomogram model for predicting relapse risk in primary membranous nephropathy (PMN). Methods The clinical, laboratory, pathological and follow-up data of patients with biopsy-proven membranous nephropathy were collected in the Affiliated Hospital of Qingdao University. A total of 400 PMN patients who achieved remission were assigned to the development group (n = 280) and validation group (n = 120) randomly. Cox regression analysis was performed in the development cohort to determine the predictive factors of relapse in PMN patients, a nomogram model was established based on the multivariate Cox regression analysis and validated in the validation group. C-index and calibration plots were used to evaluate the discrimination and calibration performance of the model respectively. Result Hyperuricemia (HR = 2.938, 95% CI 1.875–4.605, p < 0.001), high C-reactive protein (CRP) (HR = 1.147, 95% CI 1.086–1.211, p < 0.001), and treatment with calcineurin inhibitors with or without glucocorticoids (HR = 2.845, 95%CI 1.361–5.946, p = 0.005) were independent risk factors, while complete remission (HR = 0.420, 95%CI 0.270–0.655, p < 0.001) was a protective factor for relapse of PMN according to multivariate Cox regression analysis, then a nomogram model for predicting relapse of PMN was established combining the above indicators. The C-indices of this model were 0.777 (95%CI 0.729–0.825) and 0.778 (95%CI 0.704–0.853) in the development group and validation group respectively. The calibration plots showed that the predicted relapse probabilities of the model were consistent with the actual probabilities at 1, 2 and 3 years, which indicated favorable performance of this model in predicting the relapse probability of PMN. Conclusions Hyperuricemia, remission status, CRP and therapeutic regimen were predictive factors for relapse of PMN. A novel nomogram model with good discrimination and calibration was constructed to predict relapse risk in patients with PMN early.

[1]  Jingye Pan,et al.  Prediction model of renal function recovery for primary membranous nephropathy with acute kidney injury , 2022, BMC Nephrology.

[2]  Zhuoli Zhang,et al.  Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal. , 2022, Rheumatology.

[3]  Li Zhu,et al.  Influencing Factors of Recurrence of Nonvalvular Atrial Fibrillation after Radiofrequency Catheter Ablation and Construction of Clinical Nomogram Prediction Model , 2022, International journal of clinical practice.

[4]  Gabriel Ștefan,et al.  Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy , 2022, Renal failure.

[5]  B. Rovin,et al.  KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases , 2021, KIDNEYS.

[6]  Lijie He,et al.  Microhematuria Enhances the Risks of Relapse and Renal Progression in Primary Membranous Nephropathy , 2021, Frontiers in Medicine.

[7]  Liang Zhao,et al.  Hyperuricemia and hypertriglyceridemia indicate tubular atrophy/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy , 2021, International Urology and Nephrology.

[8]  V. Tesar,et al.  Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy , 2021, Frontiers in Immunology.

[9]  Hong-mei Wang,et al.  The association of anti-PLA2R with clinical manifestations and outcomes in idiopathic membranous nephropathy: a meta-analysis , 2020, International Urology and Nephrology.

[10]  Xin J. Zhou,et al.  Spectrum of biopsy proven renal diseases in Central China: a 10-year retrospective study based on 34,630 cases , 2020, Scientific Reports.

[11]  Yusuke Suzuki,et al.  Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS) , 2020, Clinical and Experimental Nephrology.

[12]  Yusuke Suzuki,et al.  Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS) , 2020, Clinical and Experimental Nephrology.

[13]  H. Reich,et al.  Serum Albumin at Partial Remission Predicts Outcomes in Membranous Nephropathy , 2020, Kidney international reports.

[14]  Fan Lin,et al.  Serum uric acid is an independent predictor of renal outcomes in patients with idiopathic membranous nephropathy , 2019, International Urology and Nephrology.

[15]  B. Rovin,et al.  Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. , 2019, The New England journal of medicine.

[16]  C. Herencia,et al.  Glomerular Hematuria: Cause or Consequence of Renal Inflammation? , 2019, International journal of molecular sciences.

[17]  M. Ando,et al.  Urinary protein and renal prognosis in idiopathic membranous nephropathy: a multicenter retrospective cohort study in Japan , 2018, Renal failure.

[18]  J. Wetzels,et al.  Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. , 2018, Kidney international.

[19]  G. Remuzzi,et al.  Treatment of membranous nephropathy: time for a paradigm shift , 2017, Nature Reviews Nephrology.

[20]  Sohee Oh,et al.  Factors affecting the long-term outcomes of idiopathic membranous nephropathy , 2017, BMC Nephrology.

[21]  D. Cattran,et al.  Membranous nephropathy: integrating basic science into improved clinical management. , 2017, Kidney international.

[22]  V. Jha,et al.  Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide , 2017, Kidney international reports.

[23]  Jun Zhou,et al.  Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials. , 2017, Autoimmunity reviews.

[24]  K. Nath,et al.  A Proposal for a Serology-Based Approach to Membranous Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[25]  V. Jha,et al.  Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial , 2016, Nephrology.

[26]  Yuanyuan Xie,et al.  Association of Relapse with Renal Outcomes under the Current Therapy Regimen for IgA Nephropathy: A Multi-Center Study , 2015, PloS one.

[27]  A. Thompson,et al.  Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.

[28]  G. Remuzzi,et al.  Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.

[29]  Sana F. Khan,et al.  Balancing cancer risk and efficacy of using cyclophosphamide to treat idiopathic membranous nephropathy. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[30]  Chapter 7: Idiopathic membranous nephropathy , 2012, Kidney international supplements.

[31]  David M. Beck,et al.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. , 2009, The New England journal of medicine.

[32]  B. Rovin,et al.  Uric acid and cardiovascular risk. , 2009, The New England journal of medicine.

[33]  Kwanghee Kim,et al.  The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A , 2008, Nature Medicine.

[34]  A. Wasilewska,et al.  High-sensitivity C-reactive protein (hs-CRP) level in children with nephrotic syndrome , 2007, Pediatric Nephrology.

[35]  S. Haffner,et al.  Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. , 2000, Kidney international.

[36]  K. Dahan,et al.  Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. , 2017, Journal of the American Society of Nephrology : JASN.

[37]  J. Wetzels,et al.  Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. , 2014, Journal of the American Society of Nephrology : JASN.